NHS CGM for Type 2 Diabetes UK 2026: Who Qualifies, Which Devices and What to Do If You Do Not

NHS-funded continuous glucose monitoring in type 2 diabetes is currently restricted to specific insulin-treated groups under NICE NG28 and QS209. The February 2026 NG28 update reinforced this rather than extending CGM to non-insulin T2D. If you do not qualify, self-funding is the realistic alternative.

You have noticed a small white circle on your sister-in-law’s upper arm. She glances at her phone and tells you her glucose is sitting at 6.3 mmol per litre. You have type 2 diabetes. You take metformin and gliclazide, or perhaps Wegovy, or perhaps a once-a-day basal insulin. You have seen the LinkedIn posts and the TikTok videos about ZOE, Veri and Levels. The question forming in your mind is simple. Can you get one of these things on the NHS, and if so, which one, and if not, what do you do.

This article is for you. It is a calm UK explainer drawn from NICE guideline NG28 (updated 18 February 2026), NICE Quality Standard QS209, the June 2025 Pan-London Implementation Document on CGM in type 2 diabetes, and current ICB commissioning practice. The aim is honest answers – no false hope, no blanket no. What follows: what CGM actually is, who currently qualifies on the NHS, why your postcode matters, which devices are funded, what the evidence shows, what self-funding costs, and how to have the conversation with your GP or diabetes team.

What a continuous glucose monitor actually is and why people want one

A continuous glucose monitor – usually called a CGM, or in its commonest UK form a flash glucose monitor – is a small disc-shaped sensor that sits on the back of the upper arm or the abdomen. A hair-thin filament under the skin reads the glucose in the interstitial fluid between cells, sending a reading every one to five minutes to a smartphone app or a dedicated reader.

There are two broad categories. Flash glucose monitoring, the FreeStyle Libre 2 and Libre 3 from Abbott, either requires scanning with a phone (Libre 2) or streams continuously (Libre 3). Real-time CGM – Dexcom ONE+, Dexcom G7, Medtronic Guardian Sensor 4 – streams to a phone continuously and can sound an alarm for high or low glucose. Sensors typically last 10 to 14 days. Most modern sensors do not require finger-prick calibration.

People with type 2 diabetes want CGM for several legitimate reasons. Spotting silent overnight lows on insulin. Understanding which foods spike glucose hardest. Building motivation for dietary change by seeing the result of each meal in real time. Reducing the daily number of finger pricks – some patients on intensive insulin regimens are doing six to eight per day. And generating evidence of hypoglycaemia to share with the diabetes team at the next review.

The catch is that the NHS does not offer CGM to every T2D patient who would find it useful. The current rules are specific. Worth knowing them properly before you book the GP appointment.

NICE NG28 and QS209 – who actually qualifies for NHS CGM with T2D

NICE guideline NG28 (Type 2 diabetes in adults: management, updated 18 February 2026) and NICE Quality Standard QS209 between them set the eligibility rules. UK Integrated Care Boards translate these into local funded device lists.

NICE recommends NHS-funded CGM for type 2 adults in five specific situations.

First, adults on multiple daily insulin injections (MDI – usually basal plus three meal-time bolus doses) who cannot self-monitor blood glucose by capillary finger-prick because of a physical or cognitive condition.

Second, adults on insulin (any regimen) who need help monitoring blood glucose because of recurrent or severe hypoglycaemia.

Third, adults on MDI who would otherwise need to perform eight or more finger-prick tests per day.

Fourth, adults on MDI with impaired hypoglycaemia awareness – that is, the loss of the warning symptoms that previously alerted them to a low.

Fifth, pregnant women with type 2 diabetes requiring insulin. This group is treated through the same pathway as pregnant women with type 1 diabetes.

Some local ICBs additionally fund CGM for adults on MDI with HbA1c persistently above 8.5% despite optimised care.

Importantly, the February 2026 NG28 update did not extend CGM eligibility to non-insulin type 2 diabetes. If you are managed on metformin, gliclazide, an SGLT2 inhibitor, a GLP-1 receptor agonist such as Wegovy, Mounjaro or Ozempic, or once-daily basal insulin only without problematic hypoglycaemia, you currently do not meet the NHS CGM criteria. That can be hard to hear when you are working hard at managing your diabetes. It is the current rule, not a judgement on your effort.

The local ICB / postcode reality – why two patients get different answers

NICE sets the floor. Your local Integrated Care Board sets the ceiling. NHS England runs through 42 ICBs. Each ICB has its own diabetes formulary that translates NICE recommendations into a local list of approved CGM devices and explicit funding rules.

Some ICBs are notably more permissive. The Pan-London Implementation Document for CGM in T2D, published June 2025, harmonised T2D CGM access across London ICBs and widened eligibility for MDI patients. Other parts of England are more restrictive because of local budget pressures.

The consequence is uncomfortable but real. Two patients with identical clinical profiles – same insulin regimen, same HbA1c, same hypoglycaemia history – can get different answers if they live in different postcodes. A March 2026 published analysis (PMC12535368) documented significant inequities in CGM access across England by ethnicity and socioeconomic factors. That data is informing the 2026-27 ICB commissioning round, but it has not yet flattened the postcode lottery.

What this means practically. Your first stop is your diabetes nurse or GP, who knows what your local ICB funds. Ask explicitly to see the local diabetes formulary – it is usually a public document on the ICB website. If your clinical situation is borderline, ask whether your team can submit an Individual Funding Request (IFR) on your behalf. IFRs take time but they do succeed in clear cases.

If the answer comes back as no, the second question worth asking is what would need to change in your management for the answer to become yes. Sometimes a structured escalation from once-daily basal to multiple daily injections is clinically appropriate and brings CGM eligibility with it.

Devices the NHS funds in 2026 and what to ask for

The exact device list depends on your local ICB formulary. The most commonly NHS-funded sensors for type 2 diabetes in June 2026 are these.

FreeStyle Libre 2 Plus by Abbott – the most-prescribed flash glucose sensor across NHS England. 14-day sensor life. Optional high/low alarms. Direct phone-app reading. The workhorse.

FreeStyle Libre 3 – Abbott’s newer model with continuous streaming to the phone rather than the scanning gesture. Increasingly common as ICB formularies update.

Dexcom ONE+ – approved across most ICBs for T2D patients meeting the eligibility criteria. 10-day sensor life. Continuous streaming with low and high alarms.

Dexcom G7 – increasingly available. Worth noting that Dexcom is phasing out the G6 from April 2026 and replacing it with G7, so any new Dexcom prescription in June 2026 onwards is likely to be G7 rather than G6.

Medtronic Guardian Sensor 4 – usually paired with Medtronic insulin pump therapy and less common in straightforward T2D unless you are on a pump.

Your diabetes team will tell you which device is on the local list. Increasingly, they will give you a clinical choice between flash and real-time CGM based on your situation – real-time CGM with alarms is preferred for those with impaired hypo awareness, flash is usually preferred for those who simply need readings without alarms.

NHS sensors come with the standard prescription charge structure. Free if you have a medical exemption certificate (HC2), if you are over 60 in England, or if you have one of the other standard exemptions. Otherwise the standard prescription charge per item.

What CGM evidence actually shows in T2D on insulin

The published evidence base for CGM in insulin-treated type 2 diabetes is strong enough to support the NICE recommendation, but not yet strong enough to extend to non-insulin T2D.

Multiple randomised controlled trials and meta-analyses show CGM in insulin-treated T2D reduces HbA1c by 0.3 to 0.5 percentage points on average versus self-monitored blood glucose. The benefit is largest in MDI patients – basal plus three meal-time bolus doses – and smaller in basal-only patients.

CGM also reduces time spent below 4.0 mmol per litre – the low-glucose zone – and increases time-in-range, the percentage of the day spent between 3.9 and 10.0 mmol per litre. Both are important metrics that correlate with reduced long-term complications, particularly retinopathy and nephropathy. Severe hypoglycaemic events fall significantly in MDI patients using CGM. Quality of life improves measurably: fewer finger-prick injuries, lower diabetes distress scores, better engagement with diabetes self-management.

Why this evidence does not yet extend to non-insulin T2D. Trials in tablets-only T2D show smaller HbA1c reductions and inconsistent long-term effects. Without robust evidence, NICE cannot recommend NHS funding given the opportunity cost. Over four million UK adults have T2D, versus around 400,000 with T1D, so the budget implications of universal T2D CGM would be very large.

This is not a permanent judgement. Trials are ongoing. NCT07336329 and similar 2025-26 studies are testing periodic versus continuous CGM in non-insulin T2D. The evidence may shift in coming years. For now, the NHS line is clear: CGM is for insulin-treated T2D meeting specific criteria.

What it costs if you self-fund and the routes that exist

If you do not qualify under NHS criteria, the choice is to self-fund privately or to wait.

Current UK retail prices in June 2026:

• FreeStyle Libre 2 Plus sensor – around 60 to 70 pounds per 14-day sensor, so roughly 130 to 150 pounds per month for continuous wear.
• FreeStyle Libre 3 sensor – similar price range to Libre 2 Plus.
• Dexcom ONE+ sensor – around 75 to 90 pounds per 10-day sensor, so roughly 225 to 270 pounds per month.
• Dexcom G7 sensor – similar to ONE+.

All sensors require a smartphone or a compatible reader, available at additional cost from the manufacturer (sometimes free with a starter pack). VAT-free for diabetes use on a VAT exemption declaration – most retailers will guide you through this at checkout.

Practical routes if you self-fund.

A one-month trial. Buy a single sensor pack, wear continuously for two to four weeks, download the data, discuss with your diabetes team. This is often enough to settle whether CGM materially changes how you manage your diabetes.

Intermittent use. A fortnight every three months can give useful trend data without the full annual cost.

A subsidised package. Some private diabetes clinics offer CGM as part of a care package, including data review with a specialist consultant. Worth checking what is available locally.

Wellness-brand CGM. Direct-to-consumer services – ZOE, Veri, Levels, Lingo – sell CGM as a metabolic insight tool. These are paid wellness services, not NHS medical care, but they are a legitimate paid option for self-experimentation. Just be clear with yourself that you are buying insight, not treatment.

How to ask your GP or diabetes team about CGM

Most NHS CGM prescribing for type 2 diabetes happens through the diabetes nurse rather than the GP, but the conversation usually starts with the GP.

Book a routine appointment – 10 minutes is enough for the opening conversation, with a follow-up booked for review.

Use clear language. Start with: I have type 2 diabetes managed by – and then list your current treatment. I am interested in NHS continuous glucose monitoring. Can we go through the eligibility criteria together?

Then state your specific situation. How many insulin injections you take per day, if any. Whether you have had any hypoglycaemic episodes in the last six months. How many finger-prick tests you currently do per day. Whether you have impaired hypoglycaemia awareness – that is, whether your warning symptoms still arrive before a low.

Bring three things. A recent HbA1c result. A brief log of any low-glucose episodes from the last three to six months. The names of all your current diabetes medications.

Be honest about what you want CGM for. If your goal is purely lifestyle, weight loss or curiosity, the honest answer is the NHS will not fund this and self-funding is your route. If your goal is to manage problematic hypoglycaemia on insulin, you may qualify and the conversation is about formal escalation to the diabetes team.

Ask explicitly: do I meet the NICE QS209 criteria? Can we look at the local ICB diabetes formulary together? If I am borderline, can we submit an Individual Funding Request? If I do not currently qualify, what changes in my diabetes management would change that?

Agree a clear plan and a review date. That structure prevents the appointment ending in a vague no without options.

Frequently Asked Questions

Can I get a continuous glucose monitor on the NHS if I have type 2 diabetes?

Yes, but only if you meet specific NICE NG28 and QS209 criteria. NHS CGM in T2D is generally restricted to adults on multiple daily insulin injections who have problematic hypoglycaemia, impaired hypoglycaemia awareness, cannot self-finger-prick, or would otherwise need eight or more tests per day. Some local ICBs additionally fund CGM for MDI patients with HbA1c persistently above 8.5%. T2D on tablets or once-daily insulin without these issues does not currently qualify on the NHS in 2026.

Did the February 2026 NICE NG28 update expand CGM eligibility for type 2 diabetes?

No. The February 2026 NICE NG28 update was the largest revision of type 2 diabetes guidance since 2015, but the major changes were to medication. SGLT2 inhibitors became first-line alongside metformin, dual therapy first-line, and triple therapy first-line for established cardiovascular disease. CGM eligibility was reinforced, not extended. NHS-funded CGM in T2D remains tied to insulin therapy with the additional criteria from NICE QS209. Non-insulin T2D patients still do not qualify on the NHS.

Which CGM devices does the NHS prescribe for type 2 diabetes in 2026?

The exact list depends on your local ICB diabetes formulary, but the most-prescribed NHS-funded sensors in T2D in 2026 are FreeStyle Libre 2 Plus, FreeStyle Libre 3 (Abbott), Dexcom ONE+ and Dexcom G7. Medtronic Guardian Sensor 4 is used mostly with Medtronic pump therapy. Dexcom is phasing out the G6 from April 2026, replacing it with G7. Your diabetes team will tell you which device is locally funded and will increasingly offer clinical choice between flash and real-time CGM.

What does CGM cost if I self-fund it in the UK in 2026?

Roughly 130 to 150 pounds per month for FreeStyle Libre 2 Plus or Libre 3, or 225 to 270 pounds per month for Dexcom ONE+ or G7 sensors. Sensors last 10 to 14 days depending on device. Most are VAT-free for diabetes use on a VAT exemption declaration at checkout. You can also buy a single sensor for a one-month trial, which is often enough to decide whether CGM materially changes how you manage your diabetes. Some private diabetes clinics offer subsidised CGM packages.

Why does my friend with type 1 diabetes get NHS CGM and I do not?

NHS CGM is now offered to all adults with type 1 diabetes by default, following the 2022 NICE guideline updates. Type 2 eligibility is stricter because the published evidence for CGM benefit is largest in insulin-treated patients – especially on multiple daily injections. Over four million UK adults have T2D versus around 400,000 with T1D, so the budget implications of universal T2D CGM would be very large. Trials are ongoing in non-insulin T2D and the picture may shift.

What can I do if I do not qualify for NHS CGM?

Several routes. Self-fund a one-month trial sensor and bring the data back to your diabetes team. Self-fund routinely if cost is acceptable. Ask whether your team can submit an Individual Funding Request if your situation is borderline. Consider a wellness-brand CGM (ZOE, Veri, Levels, Lingo) for metabolic insight – paid services, not NHS medical care. Focus on the diabetes management you can optimise without CGM: diet, exercise, weight loss, medication review at every appointment.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.